ClinicalTrials.gg
CompletedNCT00686517Updated Apr 5, 2017Results posted

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

A Phase 3 interventional study of Pegylated interferon alfa-2b and Ribavirin in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing peginterferon alfa-2b in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C.

Enrollment
11th of 23
130 · median 102
Started
2003
the only one that year
Phase 3
7 of 23
none open now
Registered
11th of 23
by date
Lead sponsor
8 of 23
Merck Sharp & Dohme LLC

Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, this one is the 11th largest by enrollment, is the only one that started in 2003, is one of 7 in phase 3, and was the 11th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 23 studies testing peginterferon alfa-2b in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing peginterferon alfa-2b in Hepatitis C as a file.
02

Study summary

The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C. After 12 weeks of observation from disease onset, participants will receive one of the following regimens: (1) a 24-week course of PEG-IFN monotherapy (PEG-IFN 24); or (2) a 12-week course of PEG-IFN monotherapy (PEG-IFN-12); or (3) a 12-week course of PEG-IFN in combination with ribavirin (PEG-IFN + RVB 12). After the treatment period, participants will enter a 12-month follow-up.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with acute virus (HCV).
  • Normal and Elevated serum alanine transferase () levels
  • Positive serum HCV-RNA.
  • Aged between 18 and 65 years.
  • Negative urine or serum pregnancy test (for women of ) documented within the 24-hour period prior to the first dose of the drug. Additionally, all fertile males with partners of childbearing age and females must be using reliable during the study and additionally for participants treated with ribavirin, for 6 months (for woman) and 7 months (for man and his partner) after treatment completion

Exclusion criteria

Exclusion Criteria:

  • Liver disease unrelated to infection
  • (Hgb) \<12g/dL in women and \<13g/dL in men; white blood cells (WBC) \<3,000/uL; (PLTs) \<100,000/ul
  • Women with ongoing pregnancy or who are breast feeding
  • History of severe psychiatric disease, especially depression
  • History of neurologic disease, especially epilepsy
  • History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease
  • Positive anti- (HIV) antibodies
  • Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA) (>1/80)
  • Positive surface antigen (HBsAg)
  • History of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months
  • History or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    PEG-IFN 24

    pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks

    Biological: Pegylated interferon alfa-2b

  • Experimental
    PEG-IFN 12

    pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks

    Biological: Pegylated interferon alfa-2b

  • Experimental
    PEG-IFN + RVB 12

    pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks

    Biological: Pegylated interferon alfa-2b · Drug: Ribavirin

Interventions

  • 1.5 ug/kg/week SC for 12 or 24 weeks

    Also known as: SCH 54031, PegIntron

  • Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks

    Also known as: SCH 18908, Rebetol

06

What researchers measure

Primary outcomes

  1. Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period

    SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.

    Time frame: Evaluated at the end of 6 months

Secondary outcomes

  1. Virologic Response at the End of Treatment Follow-up (ETR)

    ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks treatment (depending on treatment arm) was \<15 IU/mL.

    Time frame: At the end of treatment (either 12 weeks or 24 weeks depending on randomization).

  2. Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).

    LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was \<15 IU/mL.

    Time frame: At 12 months post-treatment (treatment period either 12 weeks or 24 weeks depending on randomization).

  3. Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization

    ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.

    Time frame: Evaluated at end of treatment (either 12 weeks or 24 weeks, depending on randomization), at 6-month follow-up visit, or at 12-month follow-up visit.

  4. Number of Participants With Rapid Virologic Response (RVR)

    Participants were considered to have RVR if serum HCV RNA level at 2 or 4 weeks of treatment was below the cut off value of the referring local laboratory of each participating site.

    Time frame: Evaluated at 2 and 4 weeks of treatment

  5. Number of Peripheral Blood Mononuclear Cells (PBMCs)

    Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.

    Time frame: Treatment Weeks 2, 4, 8, and 12

07

Results

Posted Jan 31, 2012

Participant flow

Treatment
Participant flow — Treatment
MilestonePEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
Started444343
Completed final treatment visit444343
Completed384042
Not completed631
Withdrew: Serious adverse event121
Withdrew: Adverse event200
Withdrew: Poor protocol compliance100
Withdrew: Protocol violation210
Follow-up
Participant flow — Follow-up
MilestonePEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
Started373839
Completed292829
Not completed81010

Outcome measures

PrimaryNumber of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period

SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.

Time frame:
Evaluated at the end of 6 months
Reported as:
Number · participants
Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period
participantsPEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period232021
SecondaryVirologic Response at the End of Treatment Follow-up (ETR)

ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks treatment (depending on treatment arm) was \<15 IU/mL.

Time frame:
At the end of treatment (either 12 weeks or 24 weeks depending on randomization).
Reported as:
Number · participants
Virologic Response at the End of Treatment Follow-up (ETR)
participantsPEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
Virologic Response at the End of Treatment Follow-up (ETR)262827
SecondaryVirologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).

LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was \<15 IU/mL.

Time frame:
At 12 months post-treatment (treatment period either 12 weeks or 24 weeks depending on randomization).
Reported as:
Number · participants
Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).
participantsPEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).201919
SecondaryNumber of Participants Presenting With Alanine Transferase (ALT) Level Normalization

ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.

Time frame:
Evaluated at end of treatment (either 12 weeks or 24 weeks, depending on randomization), at 6-month follow-up visit, or at 12-month follow-up visit.
Reported as:
Number · participants
Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization
participantsPEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
End of Treatment283132
6-month Follow-up Period312728
12-month Follow-up Period272323
SecondaryNumber of Participants With Rapid Virologic Response (RVR)

Participants were considered to have RVR if serum HCV RNA level at 2 or 4 weeks of treatment was below the cut off value of the referring local laboratory of each participating site.

Time frame:
Evaluated at 2 and 4 weeks of treatment
Reported as:
Number · participants
Number of Participants With Rapid Virologic Response (RVR)
participantsPEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12
2 weeks after start of treatment242523
4 weeks after start of treatment283534
SecondaryNumber of Peripheral Blood Mononuclear Cells (PBMCs)

Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.

Time frame:
Treatment Weeks 2, 4, 8, and 12

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN 12—3/43 (7%)37/43 (86%)
PEG-IFN 24—4/44 (9.1%)43/44 (97.7%)
PEG-IFN + RVB 12—4/43 (9.3%)42/43 (97.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPEG-IFN 12PEG-IFN 24PEG-IFN + RVB 12
HypoAcusisEar and labyrinth disorders1/430/440/43
DacryocystitisInfections and infestations0/430/441/43
Transaminases IncreasedInvestigations1/430/440/43
Lung Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/441/43
HeadacheNervous system disorders1/430/440/43
Optic NeuritisNervous system disorders0/430/441/43
ManiaPsychiatric disorders0/430/441/43
Autoimmune thyroiditisEndocrine disorders0/431/440/43
DiarrheaGastrointestinal disorders0/431/440/43
VomitingGastrointestinal disorders0/431/440/43
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPEG-IFN 12PEG-IFN 24PEG-IFN + RVB 12
GranulocytopeniaBlood and lymphatic system disorders22/4332/4426/43
LeukopeniaBlood and lymphatic system disorders31/4330/4431/43
PyrexiaGeneral disorders27/4330/4428/43
ArthralgiaMusculoskeletal and connective tissue disorders11/4313/4413/43
HeadacheNervous system disorders11/4313/4412/43
AstheniaGeneral disorders12/4311/447/43
PainGeneral disorders8/439/447/43
Transaminases IncreasedInvestigations4/438/442/43
Platelet Count DecreasedInvestigations7/435/441/43
NauseaGastrointestinal disorders2/437/443/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12Total
Mean36.55 ± 13.8638.32 ± 13.9538.52 ± 12.4837.79 ± 13.37
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12Total
Female1516637
Male29273793
Region of Enrollment
Region of Enrollment(participants)PEG-IFN 24PEG-IFN 12PEG-IFN + RVB 12Total
Italy444343130
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology. 2014 Jun;59(6):2101-9. doi: 10.1002/hep.26991. Epub 2014 Apr 29. PubMed 24442928 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Dec 2003
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jan 31, 2012
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686517
Collaborators
Bioikos Ambiente Srl
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Dec 2003
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jan 31, 2012
Last update
Apr 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion